SWOG clinical trial number
S9706

A Phase II Trial of High Dose Cyclophosphamide Followed by Fludarabine in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Closed
Phase
Accrual
100%
Published
Abbreviated Title
HD CTX followed by FLUDARA in B-Cell CLL
Activated
09/15/1997
Closed
03/01/1999
Participants
NCORP, Members

Research committees

Leukemia

Treatment

Cyclophosphamide Fludarabine Phosphate

Eligibility Criteria Expand/Collapse

Pathological diagnosis of B-cell CLL categorized in the intermediate or high-risk stage; no prior cytotoxic therapy for CLL, >= 18 years, PS 0-2.

Publication Information Expand/Collapse

2009

Lin28 enhances tumorigenesis and is associated with advanced human malignancies [PMC2757943; PMID19483683]

SR Viswanathan;JT Powers;W Einhorn;Y Hoshida;TL Ng;S Toffanin;M O'Sullivan;J Lu;LA Phillips;VL Lockhard;SP Shah;PS Tanwar;CH Mermel;R Beroukhim;M Azam;J Teixeira;M Meyerson;TP Hughes;JM Lovet;J Radich;CG Mullighan;TR Golub;PH Sorensen;GQ Daley Nature Genetics 41:843-848

2005

Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG Trial SWOG 9706

MA Hussein;H Gundacker;DR Head;L Elias;KA Foon;DH Boldt;S Dobin;SR Dakhil;GT Budd;FR Appelbaum Leukemia 19:1880-1886

2003

Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia

ED Hsi;KJ Kopecky;FR Appelbaum;DH Boldt;T Frey;M Loftus;MA Hussein British Journal of Haematology 120:1017-1025

2001

Encouraging response rate to sequential cyclophosphamide (Cy) followed by fludarbine phosphate (FI) in newly diagnosed B-cell chronic lymphocytic leukemia (CLL): a Southwest Oncolog Group trial.

MA Hussein;H Gundacker;L Elias;S Dakhil;D Head;F Appelbaum Proc of the American Society of Clinical Oncology 20:305a(#1217)

Prognostic significance of CD38 and CD20 expression in chronic lymphocytic leukemia (CLL) as assessed by quantitative flow cytometry.

E Hsi;KJ Kopecky;FR Appelbaum;DH Boldt;M Loftus;T Frey;MA Hussein Blood 98(11):357a(#1504)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A042001

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
49%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open